MEDNAX, Inc. (MD)
| Market Cap | 2.18B |
| Revenue (ttm) | 1.83B |
| Net Income (ttm) | 19.15M |
| Shares Out | 86.45M |
| EPS (ttm) | 0.23 |
| PE Ratio | 109.39 |
| Forward PE | 13.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 529,880 |
| Open | 25.81 |
| Previous Close | 25.74 |
| Day's Range | 25.12 - 26.07 |
| 52-Week Range | 20.27 - 35.67 |
| Beta | 2.09 |
| Analysts | Hold |
| Price Target | 28.18 (+11.5%) |
| Earnings Date | Oct 28, 2021 |
About MD
MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectan...
Financial Performance
In 2020, MEDNAX's revenue was $1.73 billion, a decrease of -2.57% compared to the previous year's $1.78 billion. Losses were -$796.49 million, -46.82% less than in 2019.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for MEDNAX stock is "Hold." The 12-month stock price forecast is 28.18, which is an increase of 11.52% from the latest price.
News
Mednax to Present at Bank of America 2021 Leveraged Finance Conference
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at Bank of America 2021 Leveraged Finance Conference
Mednax to Present at Credit Suisse 30th Annual Healthcare Conference
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at Credit Suisse 30th Annual Healthcare Conference
MEDNAX's (MD) Q3 Earnings Beat Estimates, Revenues Up Y/Y
MEDNAX's (MD) third-quarter results reflect growing revenues driven by rising patient volumes, partly offset by higher general and administrative expenses.
Mednax (MD) Q3 Earnings and Revenues Surpass Estimates
Mednax (MD) delivered earnings and revenue surprises of 9.52% and 2.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Mednax Reports Third Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax Reports Third Quarter Results
Why Mednax (MD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Mednax (MD) Earnings Expected to Grow: Should You Buy?
Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mednax 2021 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 28, 2021
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax 2021 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 28, 2021
NextGen's (NXGN) Integrated Platform Gets Leveraged by Mednax
Mednax utilizes NextGen's (NXGN) fully-integrated platform to enhance its efficacy in placing crucial information on patients' health and well-being at the physician's fingertips.
Mednax Clinical Leadership Urges Full Vaccination and All Measures to Protect Expecting Mothers and Children During C...
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Mednax provides full support of the CDC and other medical associations' recommendations that all eligible Americans be vaccinated against COVID-19.
Mednax (MD) Invests in Brave Care to Boost Pediatric Business
Mednax (MD) and Brave Care form a relationship to provide enhanced pediatric care and pursue its pipeline of pediatric clinics' plan.
Brave Care, The Leader in Technology-Powered Pediatric Clinics, Raises $25M in Series B Investment led by Mednax, Inc.
PORTLAND, Ore., Oct. 7, 2021 /PRNewswire/ -- Brave Care, the first pediatric healthcare and technology platform dedicated to improving primary and urgent care for children, today announced it has raised...
Mednax and Brave Care to Accelerate Transformation of Pediatric Primary and Urgent Care
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Mednax, Inc. and privately owned Brave Care will develop new, innovative pediatric primary and urgent care clinics throughout the United States.
The Pediatrix® and Obstetrix® Medical Group Reports Surge in Critically Ill Pregnant Patients with the COVID-19 Delta...
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #COVID19--Pediatrix® and Obstetrix® affiliated clinicians are treating more pregnant women critically ill with COVID-19 than at any point in the pandemic.
Here's Why You Should Retain MEDNAX (MD) in Your Portfolio
Riding high on its revenue stream and strategic measures, MEDNAX (MD) holds potential to reap benefits for investors.
Mednax to Present at Morgan Stanley 19th Annual Global Healthcare Conference
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax to Present at Morgan Stanley 19th Annual Global Healthcare Conference
MEDNAX's (MD) Earnings Beat Estimates in Q2, Improve Y/Y
MEDNAX's (MD) Q2 results reflect solid volumes, partly offset by escalating expenses.
Mednax (MD) Beats Q2 Earnings and Revenue Estimates
Mednax (MD) delivered earnings and revenue surprises of 24.24% and 3.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Mednax: Q2 Earnings Insights
Shares of Mednax (NYSE:MD) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 28.12% year over year to $0.41, which beat the estimate of $0.32.
Mednax Reports Second Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax Reports Second Quarter Results
Earnings Outlook For Mednax
Mednax (NYSE:MD) releases its next round of earnings this Friday, August 06. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report.
Mednax (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 11.6% in 4 Weeks, Here's Why Mednax (MD) Looks Ripe for a Turnaround
Mednax (MD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnin...
Mednax 2021 Second Quarter Conference Call/Webcast Scheduled for Friday, August 6, 2021
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Mednax 2021 Second Quarter Conference Call/Webcast Scheduled for Friday, August 6, 2021